Options on ViroPharma traded more than 13x normal levels for the name, with 5400 calls and 1400 puts changing hands. June implied volatility spiked more than 50 points to the 140% range. Shares are up 4% near $6.83 and the catalyst for the increased volume and volatility appears to be a decision regarding the Cinryze blood-disease drug, expected June 3rd. Call buyers are driving most of the flow, paying 45 cents for July 7.5s earlier today, now quoted around 80 cents. This stock is priced to move!